Evidence map›Paper›PMID 40742292›Full record

Trial reportJournal of clinical pharmacology2025

Osimertinib Cost Minimization in Non-Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat.

Niels Westra, Paul D Kruithof, Sander Croes, Robin M J M van Geel, Lizza E L Hendriks, Daan J Touw, Jos G W Kosterink, Jasper Stevens, Thijs H Oude Munnink, Paola Mian

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Niels WestraDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-3370-1618
Paul D KruithofDepartment of Clinical Pharmacy and Toxicology, CARIM, Research Institute for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, The Netherlands.
Sander CroesDepartment of Clinical Pharmacy and Toxicology, CARIM, Research Institute for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, The Netherlands.
Robin M J M van GeelDepartment of Clinical Pharmacy and Toxicology, CARIM, Research Institute for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, The Netherlands.
Lizza E L HendriksDepartment of Pulmonary Diseases, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Daan J TouwDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Jos G W KosterinkDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Jasper StevensDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Thijs H Oude MunninkDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Paola MianDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-3984-2163

Funding

ZonMw 848017002
6 · The paper itself

Abstract

Pharmacokinetic boosting can be a strategy to enhance osimertinib exposure and reduce treatment associated costs. The OSIBOOST trial demonstrated that it was feasible to boost low osimertinib plasma trough levels with cobicistat. The current study aims to establish the equivalent dose of cobicistat boosted osimertinib compared to osimertinib 80 mg once daily (QD) by population pharmacokinetic (popPK) modeling. A popPK model was developed on the pharmacokinetic data from the OSIBOOST study using NONMEM 7.4.4. Simulations were performed with cobicistat boosted osimertinib dosing regimens to evaluate their equivalence to the standard of osimertinib 80 mg QD. A dose level was assumed equivalent when the 90% confidence interval (CI) of the geometric mean ratios (GMR) for the area under the curve over 144 h (AUC

Indexed as

AcrylamidesAniline CompoundsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarbamatesCarcinoma, Non-Small-Cell LungLung NeoplasmsAdultAgedDose-Response Relationship, DrugFemaleHumansIndolesMaleMiddle AgedModels, BiologicalAcrylamidesAniline CompoundsAntineoplastic AgentsCarbamatesIndolesosimertinibPyrimidinescobicistatnon‐small cell lung cancerosimertinibpharmacokinetic boostingpopulation pharmacokinetic modeling

Identifiers

PMID40742292
PMCPMC12649290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.